SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Martin Leissl — Bloomberg via Getty Images

69

Merck

MRK

Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant’s wide-ranging portfolio was crucial to that haul—but the company’s next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb’s competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.

Looking for leads, investment insights, or competitive intelligence?

CEO

Kenneth C. Frazier

CEO Title

Chairman, President & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Kenilworth, NJ

Years on Fortune 500 List

23

Employees

68,000

Profile provided by S&P Global.
Merck is also featured in these fortune lists
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$39,8070.8%
Profits ($M)$3,920.0-11.8%
Assets ($M)$95,377
Total Stockholder Equity ($M)$40,088
Market Value — as of March 31, 2017 ($M)$174,454
Profit Ratios
Profit as % of Revenues9.8%
Profits as % of Assets4.1%
Profits as % of Stockholder Equity9.8%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)1.41
EPS % Change (from 2015)-9.6%
EPS % Change (5 year annual rate)-6.9%
EPS % Change (10 year annual rate)-3.6%
Total Return
Total Return to Investors (2016)15.1%
Total Return to Investors (5 year, annualized)13.2%
Total Return to Investors (10 year, annualized)7.0%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Merck